New Pancreatic Cancer Drug Reduces Risk of Death by 60 Percent - May 2026 Update

By Editorial Team
Daraxonrasib (RMC-6236) nearly doubles median survival in previously treated metastatic pancreatic cancer (13.2 vs. 6.7 months) with a 60% reduction in death risk. Learn about the breakthrough RAS(ON) inhibitor, side effects, trial results, cost concerns, and what it means for patients in 2026.

Pancreatic cancer remains one of the deadliest cancers, with a 5-year survival rate under 13% overall and just 3% for metastatic disease. But in May 2026, a new oral pill called daraxonrasib (also known as RMC-6236) delivered what experts are calling “historic” and “practice-changing” results.In the pivotal Phase 3 RASolute 302 trial, daraxonrasib doubled median overall survival and cut the risk of death by 60% compared to standard chemotherapy — all while being better tolerated for many patients. 



Here’s everything you need to know about this groundbreaking pancreatic cancer treatment, including the science, real-world implications, side effects, cost debates, and expert perspectives.
What Is Daraxonrasib and How Does It Work?Daraxonrasib is a first-in-class RAS(ON) multi-selective inhibitor developed by Revolution Medicines. It targets the active (GTP-bound) form of RAS proteins — the “undruggable” driver behind more than 90% of pancreatic ductal adenocarcinoma (PDAC) cases.

Unlike traditional chemotherapy that attacks rapidly dividing cells indiscriminately, daraxonrasib is a targeted oral therapy taken once daily (300 mg). It works by locking RAS in its “on” state, preventing the downstream signaling that fuels tumor growth in KRAS-mutant (G12, G13, Q61) and even some wild-type RAS tumors. This is a major leap forward: RAS mutations were long considered impossible to drug effectively. Daraxonrasib’s non-covalent tri-complex approach changes that.RASolute 302 Phase 3 Trial Results: Unprecedented Survival GainsThe global, randomized Phase 3 RASolute 302 trial (NCT06625320) enrolled ~500 patients with previously treated metastatic PDAC. Participants had progressed after first-line therapy and were randomized to daraxonrasib monotherapy or investigator’s choice of chemotherapy.

Key Results (presented at ASCO 2026 Plenary Session and published in NEJM):
  • Median Overall Survival (OS): 13.2 months (daraxonrasib) vs. 6.7 months (chemotherapy)
    → Hazard ratio 0.40 (60% reduction in risk of death, p < 0.0001)
  • Median Progression-Free Survival (PFS): 7.2–7.3 months vs. 3.5–3.6 months (HR 0.45–0.49)
  • Objective Response Rate (ORR): ~31–33% vs. ~11–12% (nearly tripled)
Benefits were consistent across RAS G12-mutant tumors (91.8% of patients) and the overall population. The trial met all primary and key secondary endpoints with final OS/PFS data at interim analysis.

Oncologists at ASCO 2026 gave the presentation standing ovations — a rare reaction in oncology circles. Pancreatic Cancer Action Network (PanCAN) called it a potential new standard of care for second-line metastatic PDAC.Side Effects: Manageable Compared to Chemo?Daraxonrasib’s safety profile is described as “generally well tolerated” with no new signals.
Common side effects (any grade):
  • Rash (86–90%)
  • Diarrhea
  • Stomatitis/mouth sores
  • Nausea/vomiting

Grade 3+ adverse events: ~61.8% (daraxonrasib) vs. ~69.6% (chemo)
Treatment discontinuation due to side effects: Only 1.2% vs. 11.2% on chemotherapy. Many patients and doctors note that while the rash can be inflammatory and visible, it’s often less debilitating than chemo’s severe nausea, fatigue, and neuropathy. Supportive care (topical steroids, dose adjustments) helps manage it effectively. Quality-of-life data showed delayed pain deterioration and better overall well-being versus chemo. Addressing Skepticism: The Cost and “Repurposed Drugs” DebateNot everyone is fully convinced. Some voices in the cancer community, including physician-researcher Dr. William Makis (
@MakisMedicine
on X), have questioned the hype:
  • Median survival of 13 months is still limited for stage 4 disease.
  • High cost of new oncology drugs (estimates for similar agents exceed $200k–$300k/year, though official pricing is pending).
  • Claims of success with low-cost repurposed drugs (e.g., ivermectin, mebendazole, fenbendazole protocols).
These concerns are valid to discuss. New targeted therapies are expensive, and access/insurance coverage will be critical. However, the RASolute 302 data come from a large, randomized, controlled Phase 3 trial — the gold standard of evidence. No comparable Level 1 data exist yet for repurposed drug regimens in metastatic pancreatic cancer.
Daraxonrasib is already available via FDA-expanded access for eligible patients while full approval is pursued. Who Might Benefit Most?
  • Patients with previously treated metastatic PDAC (second-line setting)
  • Those with RAS mutations (vast majority)
  • Individuals who want an oral option with fewer treatment disruptions than IV chemo
Ongoing trials are exploring daraxonrasib in first-line combinations and adjuvant (post-surgery) settings (e.g., RASolute 304). Future Outlook: A Paradigm Shift for Pancreatic Cancer?This is the first RAS(ON) inhibitor to show clear survival benefit in a Phase 3 pancreatic cancer trial. Experts are now discussing earlier use, combinations with other therapies, and broader applications in other RAS-driven cancers (lung, colorectal).
Revolution Medicines plans regulatory submissions soon. If approved, daraxonrasib could become the new backbone for metastatic PDAC treatment.
Important: Pancreatic cancer treatment is highly individual. This is not a cure, but it represents meaningful progress in extending life and quality time.FAQ: Daraxonrasib Pancreatic Cancer QuestionsQ: Is daraxonrasib FDA-approved yet?
A: Not fully approved as of June 2026, but available through expanded access programs.
Q: How much better is it than chemo?
A: It nearly doubles survival time and reduces death risk by 60% with lower discontinuation rates.
Q: What are the main side effects?
A: Primarily rash, diarrhea, and mouth sores — manageable for most and less likely to force stopping treatment than chemo.
Q: Will insurance cover it?
A: Pricing details are pending approval. Patient assistance programs are expected from the manufacturer.
Q: Can I get daraxonrasib now?
A: Talk to your oncologist about expanded access or clinical trial eligibility.
Bottom line: Daraxonrasib offers real hope for people facing advanced pancreatic cancer in 2026. While challenges around cost and access remain, the science is clear: this targeted pill is changing the conversation from “months” to “more time.”
Always consult your oncologist for personalized advice. New developments in RAS-targeted therapies are moving fast — stay informed and ask about all options, including trials.
Sources include primary data from Revolution Medicines, ASCO 2026 presentations, New England Journal of Medicine publication, and peer-reviewed coverage. This article is for informational purposes only and is not medical advice.
Related: 

Comments

Post a Comment

Popular posts from this blog

Ivermectin for Cancer Treatment: Protocols and Evidence (2026 Update)

By Editorial Team
Image
Ivermectin is a drug primarily used to treat parasitic infections, and it has attracted research interest for its potential biological effects in cancer models, particularly within integrative and experimental treatment contexts. However, current mainstream oncology guidelines do not support ivermectin as a standard or evidence-based treatment for cancer, especially as a substitute for established therapies such as immunotherapy, targeted therapy, chemotherapy, or radiation. Access to modern cancer care also remains uneven globally. Advanced diagnostic testing, molecular profiling, and novel therapies are often more accessible in high-income healthcare systems or through comprehensive insurance coverage. In contrast, patients in lower-resource or impoverished settings may face significant barriers to timely diagnosis and access to cutting-edge treatments. In this context, repurposed drugs—including ivermectin—are sometimes discussed in research and public discourse due to their low c...
Read more

Fenbendazole and the Joe Tippens Protocol: Evidence, Risks, and Current Perspective (2026 Update)

By Editorial Team
Image
Introduction The Joe Tippens Protocol revolves around the off-label use of fenbendazole (a veterinary dewormer commonly sold as Panacur C or Safe-Guard) combined with various supplements for cancer. The Protocol has been gaining rapid interest over the past years following some  fenbendazole advanced cancer success stories . Joe Tippens popularized this approach after claiming it contributed to his remission from metastatic small-cell lung cancer in 2017. As of 2026, Joe Tippens remains alive and reports being cancer-free for over 8 years, continuing a maintenance version of the protocol. Fenbendazole is marketed for animals (e.g., Panacur C, Safe-Guard ) and has no regulatory approval for human cancer treatment . Evidence for anticancer effects is primarily preclinical or anecdotal , and clinical trials in humans are lacking. Important Disclaimer: Fenbendazole is not approved by the FDA, EMA, or any regulatory body for human use or canc...
Read more

Fenbendazole and Ivermectin for Cancer: A Case Series of Over 700 Patients (2026)

By Editorial Team
Image
Anecdotal reports and preliminary studies suggest that ivermectin and fenbendazole, both antiparasitic drugs, may have potential anticancer effects when used alongside other treatments.  Many people immediately dismiss the potential of ivermectin and fenbendazole when they learn it is “horse or dog medicine”. That initial reaction is overcome when genuine human success stories are told including the lack of serious side effects. The testimonials you are about to read are from individuals who have bravely shared their experiences in the hope of inspiring and uplifting others. These are raw human accounts, unfiltered by gatekeepers—not peer-reviewed studies—but they offer insights that may be valuable to those searching for options. However, we acknowledge that robust clinical trials are needed to provide more conclusive scientific evidence. Contents: Editor's Preface Introduction Fenbendazole and Ivermectin Case Series Compilation (alphabetical) Breast Cancer Success Stories  (...
Read more

Top 10 Cancer Fighting Supplements: Evidence Based Literature Review (2026 Update)

By Editorial Team
Image
Are you overwhelmed by conflicting advice on cancer, diet, and supplements ? You’re not alone. With so many claims out there, it’s hard to separate fact from fiction . Can certain foods lower your cancer risk ? Are some foods increasing it without you realizing? What about vitamin and mineral supplements —do they help prevent cancer, or could they actually increase your risk ? The term " anti-cancer supplements " can be misleading. While some nutrients support the body in cancer prevention or treatment, others may interfere with therapies or even pose risks. There are presently over 1,500 herbs and food supplements in commerce, many of them with claims in use against cancer. This guide compiles over 500 scientific r...
Read more

Fact Check: Can Ivermectin and Fenbendazole Help Treat Cancer?

By Editorial Team
Image
Ivermectin and fenbendazole, originally developed as antiparasitic drugs, are sparking hope in the fight against cancer, fueled by inspiring stories like those shared by actor  Mel Gibson on The Joe Rogan Experience , where he celebrated friends’ remarkable recoveries. While these medications aren’t yet standard cancer treatments, early research is uncovering exciting potential. Scientists are encouraged by promising lab studies and are calling for more clinical trials to confirm their effectiveness and ensure safe use in humans, paving the way for innovative, accessible therapies that could transform lives. Introduction and Context According to a January 22, 2025 fact-check article by AFP: "The anti-parasitic drugs ivermectin and fenbendazole are not currently recommended for cancer, but posts spread across social media touting the medications after actor  Mel Gibson claimed on the Joe Rogan Experience  that they cured his friends' cases of the disease. Oncology ex...
Read more

Exploring Ivermectin, Mebendazole and Fenbendazole as Aggressive Cancer Treatments: Research, Protocols, and Controversies (2025)

By Editorial Team
Image
Fenbendazole and ivermectin, both antiparasitic drugs that have shown potential in cancer treatment through several mechanisms, such as slowing cancer cell growth and boosting the immune response. Fenbendazole is being studied for its ability to disrupt energy production in cancer cells, effectively hindering their growth. Ivermectin, on the other hand, has been explored in combination with checkpoint inhibitors to boost the immune system's response to tumors—especially in challenging cases like triple-negative breast cancer. Introduction Cancer remains a leading cause of morbidity and mortality worldwide, with an increasing incidence of aggressive and treatment-resistant tumors such as triple-negative breast cancer (TNBC), pancreatic adenocarcinoma, and glioblastoma. Despite significant advances in targeted therapies and immunotherapies, many patients continue to face limited effective options, highlighting an urgent need for novel, affordable, and accessible treatment strategies....
Read more

Fenbendazole vs Ivermectin for Cancer: Differences and Which Is Better?

By Editorial Team
Image
Cancer patients are increasingly inquiring about the use of the anthelmintic drugs Fenbendazole (FenBen) and Ivermectin (IVM) as potential treatments for cancer. Notably, these patients typically fall into two distinct groups, neither of which represents the usual stage 1 or 2 cancer cases where conventional therapies often show promise. The first group consists of older men whose lung or prostate cancer has recurred. Having undergone conventional treatments previously without success, they express skepticism about its effectiveness this time around. The second, larger group comprises younger patients under 40 dealing with aggressive breast cancer, colorectal cancer, or lymphoma—forms of early-onset cancers that appear to lack the typical mutations observed in traditional cases. This article aims to delve into the differences between Fenbendazole and Ivermectin by examining their me...
Read more

Fenbendazole and Cancer: What the Science Really Shows (Evidence, Risks & Open Questions)

By Editorial Team
Image
Abstract Background:  Fenbendazole (FBZ), a benzimidazole anthelmintic approved for veterinary use, has attracted attention for potential anticancer activity based on laboratory findings and widespread anecdotal reports.  Objective:  To critically appraise the current evidence on fenbendazole and cancer using a peer‑review style framework.  Methods:  Narrative review of preclinical studies, publicly reported human case narratives, and safety signals, with emphasis on evidence hierarchy and translational limitations.  Results:  Preclinical data demonstrate antiproliferative effects via microtubule disruption and metabolic stress in vitro and in animal models. Human evidence is limited to uncontrolled case reports; no Phase I–III clinical trials or regulatory approvals for oncology exist. Safety data in humans are sparse, with hepatotoxicity signals reported.  Conclusions:  Fenben...
Read more

Dr. William Makis's Recommended Ivermectin Dosages for Cancer (2026)

By Editorial Team
Image
Dr. William Makis, a radiologist and cancer researcher, has developed a "hybrid orthomolecular" protocol that incorporates ivermectin as a repurposed drug for cancer treatment. This approach targets cancer stem cells and mitochondrial dysfunction, often in combination with other therapies like benzimidazoles (e.g., mebendazole or fenbendazole), vitamins, and dietary changes. The protocol is based on preclinical studies, case reports, and his clinical observations, but it remains experimental and unapproved by regulatory bodies like the FDA for cancer use. Dosages are weight-based (e.g., for a 70 kg/154 lb person, 1 mg/kg = 70 mg) and stratified by cancer severity: low-grade (early-stage or slow-growing), intermediate-grade (moderately progressive), or high-grade (aggressive, metastatic, or "turbo" cancers). Always consult a healthcare provider for personalization, monitoring (e.g., liver/kidney function), and integration with conventional treatments. Key Ivermectin...
Read more

Fenbendazole and Ivermectin for Stage 4 Pancreatic Cancer: A Compilation of Case Reports and Mechanistic Insights (2026)

By Editorial Team
Image
Summary Background: Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal malignancies, with limited effective therapies and poor survival, especially in stage 4 disease. Repurposing antiparasitic agents such as fenbendazole and ivermectin has garnered interest due to their demonstrated anti-cancer properties in preclinical studies. Methods: We reviewed and synthesized 35 detailed case reports from 2022 to 2026 documenting the clinical use of fenbendazole and ivermectin, alone or in combination with standard therapies, in patients with advanced pancreatic cancer. Tumor markers, imaging outcomes, and clinical responses were analyzed alongside mechanistic literature. Results: Across cases, patients exhibited marked reductions in CA19-9 tumor markers (often >70%), significant tumor shrinkage on imaging, and improved clinical status. Responses were observed even in chemotherapy-resistant and metastatic disease. Mechanistic studies support multiple anti-cancer effects of...
Read more